119 related articles for article (PubMed ID: 38588642)
1. Measurements regarding a combined therapy concept for ophthalmic tumors consisting of brachytherapy and x-rays.
Manke H; Fluehs D; Stroth M; Bechrakis NE; Foerster AMH; Albrecht J
Biomed Phys Eng Express; 2024 Jun; 10(4):. PubMed ID: 38588642
[No Abstract] [Full Text] [Related]
2. Dosimetry of ruthenium-106 ophthalmic applicators with thin layer thermoluminescence dosimeters - Clinical quality control.
Krause F; Möller M; Risske F; Siebert FA
Z Med Phys; 2020 May; 30(2):142-147. PubMed ID: 31818650
[TBL] [Abstract][Full Text] [Related]
3. Calculation of dose distributions for 12 106Ru/106Rh ophthalmic applicator models with the PENELOPE Monte Carlo code.
Hermida-López M
Med Phys; 2013 Oct; 40(10):101705. PubMed ID: 24089895
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo skin dose simulation in intraoperative radiotherapy of breast cancer using spherical applicators.
Moradi F; Ung NM; Khandaker MU; Mahdiraji GA; Saad M; Abdul Malik R; Bustam AZ; Zaili Z; Bradley DA
Phys Med Biol; 2017 Jul; 62(16):6550-6566. PubMed ID: 28708603
[TBL] [Abstract][Full Text] [Related]
5. [Optimizing target volume assessment in irradiation of intraocular melanomas with ruthenium applicators].
Poier E; Langmann G; Leitner H; Vidic B
Fortschr Ophthalmol; 1991; 88(2):158-60. PubMed ID: 1855736
[TBL] [Abstract][Full Text] [Related]
6. Comparison between beta radiation dose distribution due to LDR and HDR ocular brachytherapy applicators using GATE Monte Carlo platform.
Mostafa L; Rachid K; Ahmed SM
Phys Med; 2016 Aug; 32(8):1007-18. PubMed ID: 27499370
[TBL] [Abstract][Full Text] [Related]
7. The three-dimensional scintillation dosimetry method: test for a 106Ru eye plaque applicator.
Kirov AS; Piao JZ; Mathur NK; Miller TR; Devic S; Trichter S; Zaider M; Soares CG; LoSasso T
Phys Med Biol; 2005 Jul; 50(13):3063-81. PubMed ID: 15972981
[TBL] [Abstract][Full Text] [Related]
8. Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye.
Asadi S; Vaez-zadeh M; Masoudi SF; Rahmani F; Knaup C; Meigooni AS
J Appl Clin Med Phys; 2015 Sep; 16(5):344–357. PubMed ID: 26699318
[TBL] [Abstract][Full Text] [Related]
9. Monte Carlo dosimetry modeling of focused kV x-ray radiotherapy of eye diseases with potential nanoparticle dose enhancement.
Yan H; Ma X; Sun W; Mendez S; Stryker S; Starr-Baier S; Delliturri G; Zhu D; Nath R; Chen Z; Roberts K; MacDonald CA; Liu W
Med Phys; 2018 Oct; 45(10):4720-4733. PubMed ID: 30133705
[TBL] [Abstract][Full Text] [Related]
10. Comparison and uncertainty evaluation of different calibration protocols and ionization chambers for low-energy surface brachytherapy dosimetry.
Candela-Juan C; Vijande J; García-Martínez T; Niatsetski Y; Nauta G; Schuurman J; Ouhib Z; Ballester F; Perez-Calatayud J
Med Phys; 2015 Aug; 42(8):4954-64. PubMed ID: 26233221
[TBL] [Abstract][Full Text] [Related]
11. [Therapy relevant weak sites in industrial quality assurance of 106Ru eye plaques].
Kaulich TW; Zurheide J; Flühs D; Haug T; Nüsslin F; Bamberg M
Strahlenther Onkol; 2001 Nov; 177(11):616-23; discussion 624-7. PubMed ID: 11757185
[TBL] [Abstract][Full Text] [Related]
12. Hydrogen nanobubbles: A novel approach toward radio-sensitization agents.
Hashemi S; Aghamiri SM; Siavashpour Z; Kahani M; Zaidi H; Jaberi R
Med Phys; 2023 Oct; 50(10):6589-6599. PubMed ID: 37278345
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of a new high-dose-rate brachytherapy Valencia applicator for larger skin lesions.
Candela-Juan C; Niatsetski Y; van der Laarse R; Granero D; Ballester F; Perez-Calatayud J; Vijande J
Med Phys; 2016 Apr; 43(4):1639. PubMed ID: 27036563
[TBL] [Abstract][Full Text] [Related]
14. A patch source model for treatment planning of ruthenium ophthalmic applicators.
Astrahan MA
Med Phys; 2003 Jun; 30(6):1219-28. PubMed ID: 12852546
[TBL] [Abstract][Full Text] [Related]
15. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators.
Flühs D; Anastassiou G; Wening J; Sauerwein W; Bornfeld N
Med Phys; 2004 Jun; 31(6):1481-8. PubMed ID: 15259651
[TBL] [Abstract][Full Text] [Related]
16. Individualized dosimetry in Ru-106 ophthalmic brachytherapy based on MRI-derived ocular anatomical parameters.
Liakopoulos DA; Perisinakis K; Solomou G; Kouvidakis A; Drakonaki EE; Bontzos G; Papadaki E; Detorakis ET
Brachytherapy; 2022; 21(6):904-911. PubMed ID: 35995724
[TBL] [Abstract][Full Text] [Related]
17. A Monte Carlo dose calculation system for ophthalmic brachytherapy based on a realistic eye model.
Miras Del Río H; Ortiz Lora A; Bertolet Reina A; Terrón León JA
Med Phys; 2021 Aug; 48(8):4542-4559. PubMed ID: 34250607
[TBL] [Abstract][Full Text] [Related]
18. Multidimensional dosimetry of ¹⁰⁶Ru eye plaques using EBT3 films and its impact on treatment planning.
Heilemann G; Nesvacil N; Blaickner M; Kostiukhina N; Georg D
Med Phys; 2015 Oct; 42(10):5798-808. PubMed ID: 26429254
[TBL] [Abstract][Full Text] [Related]
19. [Dosimetry of ruthenium applicators with an eye phantom and small volume thermoluminescence detectors].
Muskalla K; Pothmann B; Alberti W; Bornfeld N; Foerster MH; Harder D; Hermann KP; Tabor P; Sack H; Wessing A
Fortschr Ophthalmol; 1989; 86(6):655-8. PubMed ID: 2625294
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
